Life Sciences Partners et al. in €32m round for Oxthera

In addition to the Dutch, Spanish, Danish and Swedish VCs, the funding round also saw participation from Oxthera's existing backers: French VCs Kurma Partners and Idinvest, Swedish government-backed VC Industrifonden, and Sweden-based investment company Brohuvudet.

Oxthera's capital injection brings the total raised by the biotech business to more than €78m.

The funding will be used to continue development of the company's programme for treatment of primary hyperoxaluria, a potentially fatal disease where sufferers excrete excessive amounts of oxalate in their urine.

Previous funding
Prior to its most recent round, Oxthera had raised in excess of €46m in five rounds over the span of a decade, according to unquote" data.

It first raised SEK 165m from HealthCap and Scandinavian Life Science Ventures in July 2005, followed by a further €16m in 2007, when Industrifonden joined the two existing backers.

Industrifonden led an undisclosed follow-on round in June 2010, with HealthCap joining the Swedish VC in 2012 for an additional €4.67m investment.

In April 2014, HealthCap, Idinvest, Industrifonden and Kurma Partners participated in a €7.5m round for Oxthera.

Company
Oxthera is a Stockholm-based developer of treatments for hyperoxaluria.

The company was founded in 2005 and is developing hyperoxaluria drugs based on live oxalate-consuming bacteria, to prevent kidney damage in sufferers of the disease.

People
Oxthera – Elisabeth Lindner (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• Nordics
• Industrifonden
• Life Science Partners
• IDInvest Partners (AGF Private Equity)
• Venture